CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Menu
Begin main content
Home About CADTH What We Do Programs and Services Drug Reimbursement Review pembrolizumab
Back to Programs and Services

Drug Reimbursement Review

pembrolizumab

Last Updated: November 2, 2020
Result type: Reports
Project Number: PC0235-000
Product Line: Reimbursement Review

Generic Name: pembrolizumab

Brand Name: Keytruda

Manufacturer: Merck Canada Inc.

Therapeutic Area: Colorectal cancer

Indications: ​For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)

Manufacturer Requested Reimbursement Criteria1: ​For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC)

Submission Type: Initial

Tumour Type: Gastrointestinal

Project Status: Pending

Call for patient/clinician input open: November 2, 2020

Call for patient/clinician input closed: December 24, 2020

Anticipated Date: November 27, 2020

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback